Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.
PT Millennium Pharmacon International Tbk's quarterly accumulated depreciation
increased
from Dec. 2025 (Rp-116,058 Mil) to Mar. 2026 (Rp-120,659 Mil) and
increased
from Mar. 2026 (Rp-120,659 Mil) to Jun. 2026 (Rp-125,083 Mil).
PT Millennium Pharmacon International Tbk's annual accumulated depreciation
increased
from Dec. 2023 (Rp-90,123 Mil) to Dec. 2024 (Rp-97,425 Mil) and
increased
from Dec. 2024 (Rp-97,425 Mil) to Dec. 2025 (Rp-116,058 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk Accumulated Depreciation Chart
PT Millennium Pharmacon International Tbk Annual Data
PT Millennium Pharmacon International Tbk Accumulated Depreciation Calculation
The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.
What does a Accumulated Depreciation of Rp-125,083 Mil mean?
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a Accumulated Depreciation of Rp-125,083 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on PT Millennium Pharmacon International Tbk and its competitors.
Is PT Millennium Pharmacon International Tbk's Accumulated Depreciation too high?
PT Millennium Pharmacon International Tbk's current Accumulated Depreciation is Rp-125,083 Mil. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's Accumulated Depreciation compare to MCK and COR?
PT Millennium Pharmacon International Tbk's Accumulated Depreciation of Rp-125,083 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Distribution company?
A good Accumulated Depreciation depends on the Medical Distribution industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on PT Millennium Pharmacon International Tbk and its competitors. PT Millennium Pharmacon International Tbk's current Accumulated Depreciation is Rp-125,083 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp170.84, compared to a current price of Rp200.00 — trading 17.1% above its estimated fair value. The current Accumulated Depreciation is Rp-125,083 Mil. PT Millennium Pharmacon International Tbk's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current Accumulated Depreciation is Rp-125,083 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp200.00 is trading 17.1% above its estimated GF Value™ of Rp170.84.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Modestly Overvalued.
Key valuation signals for ISX:SDPC:
Accumulated Depreciation: Rp-125,083 Mil
GF Value™: Rp170.84 vs. price of Rp200.00 (17.1% above fair value)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
79GF Score
Get the complete analysis for ISX:SDPC
Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
